ReviewViruses2012
Human leukocyte antigen (HLA) class I down-regulation by human immunodeficiency virus type 1 negative factor (HIV-1 Nef): what might we learn from natural sequence variants?
Review in Viruses, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors.Journal of virology · 2015Trial
- COVID-19: Mechanisms, risk factors, genetics, non-coding RNAs and neurologic impairments.Non-coding RNA research · 2023Review
- Gene expression profiling of SARS-CoV-2 infections reveal distinct primary lung cell and systemic immune infection responses that identify pathways relevant in COVID-19 disease.Briefings in bioinformatics · 2021Article
- SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.Cells · 2020Article
- Modelling andVirus evolution · 2019Article
- HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues.Immunogenetics · 2019Article
- Conserved and variable natural killer cell receptors: diverse approaches to viral infections.Immunology · 2019Review
- Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion.Nature communications · 2019Article
- HLA Class I Downregulation by HIV-1 Variants from Subtype C Transmission Pairs.Journal of virology · 2018Article
- Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen.Frontiers in immunology · 2018Review
- Pharmacologic HIV-1 Nef blockade promotes CD8 T cell-mediated elimination of latently HIV-1-infected cells in vitro.JCI insight · 2017Article
- Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity.Journal of virology · 2015Article
- Short communication: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa.AIDS research and human retroviruses · 2014Article
- Impaired Nef function is associated with early control of HIV-1 viremia.Journal of virology · 2014Article
- Ineffectual targeting of HIV-1 Nef by cytotoxic T lymphocytes in acute infection results in no functional impairment or viremia reduction.Journal of virology · 2014Article
- A consensus surface activation marker signature is partially dependent on human immunodeficiency virus type 1 Nef expression within productively infected macrophages.Retrovirology · 2013Article
- Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes.Retrovirology · 2013Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
HIV-1 causes a chronic infection in humans that is characterized by high plasma viremia, progressive loss of CD4+ T lymphocytes, and severe immunodeficiency resulting in opportunistic disease and AIDS. Viral persistence is mediated in part by the ability of the Nef protein to down-regulate HLA molecules on the infected cell surface, thereby allowing HIV-1 to evade recognition by antiviral CD8+ T lymphocytes. Extensive research has been conducted on Nef to determine protein domains that are required for its immune evasion activities and to identify critical cellular co-factors, and our mechanistic understanding of this process is becoming more complete. This review highlights our current knowledge of Nef-mediated HLA class I down-regulation and places this work in the context of naturally occurring sequence variation in this protein. We argue that efforts to fully understand the critical role of Nef for HIV-1 pathogenesis will require greater analysis of patient-derived sequences to elucidate subtle differences in immune evasion activity that may alter clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.